Study S003330

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Safety, Tolerability, PK/PD Profile, and Efficacy of Multiple Doses of BGM0504 Injection in Overweight or Obese Subjects Without Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT06973681
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 120
Start: 2023-10-13
Primary completion: 2024-09-13
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Overweight or Obesity
Interventions: DRUG:BGM0504; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Percentage change in body weight [Week 0 to Week 24]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012174	Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Ji L, Diabetes, obesity & metabolism	2026	Randomized trial	PMID 42755112 DOI	cites ClinicalTrials.gov:NCT06973681; registry reference DERIVED:42755112